This month’s roundup of hires, acquisitions, anniversaries, and other announcements includes news from Premier Research, Cytel, ACG, and other companies.
This month’s roundup of new hires, acquisitions, anniversaries and other industry announcements includes news from Premier Research, Cytel, ACG, and other leading companies.
Premier Research has acquired strategy, regulatory and commercial specialist Camargo Pharmaceutical Services. According to the companies, the combination will bolster product planning, development and differentiation offerings.
“We are confident in this transaction knowing that we now have a deeper bench of knowledge and expertise to support our clients in all phases of their product development,” said “Sameena Sharif, president of Regulatory Professionals, a division of Premier research. “Camargo’s recognized regulatory, non-clinical development, and patient-centric product differentiation services will strongly augment the strategic and development consulting services that we have been providing for over 25 years.”
Clinical trial tech provider Cytel has named Kyle Wathen vice president of scientific strategy and innovation. He brings to the company more than two decades of adaptive clinical trial design, as well as major contributions to the first adaptive platform trial, I-SPY2.
“The growing adoption of complex designs – facilitated by enabling tools like East and Solara – is a momentous step forward for the industry,” said Wathen. “I’m dedicated to further elevating Cytel’s innovative design arsenal and empowering customers to carve a smoother, more efficient path to market.”
CPhI has announced that its CPhI Worldwide and Pharmapack Europe industry events have been given the all-clear to offer in-person programming by their host countries. CPhI Worldwide is scheduled November 9-11 in Milan, Italy; and Pharmapack Europe is slated to occur October 13-14 in Paris (with online programming scheduled September 27-October 15).
“There’s been a shift in the way pharma sources new leads and moving forward, we expect to see pharma companies with the highest growth rates utilizing a multi-platform approach, especially as the industry expands and competition for the best partners increases,” commented Cara Turner, brand director at Informa Markets. “Practically, this means starting conversations with new customers much earlier and ensuring companies fully maximize the value they get from one of their most precious commodities, the events they attend in person.”
Clinical trial tech specialist Clinical Ink has hired Janette Morgan as EVP/general manager for the EMEA market. Morgan is expected to manage the company’s global growth strategy, focusing both on commercial and study operations and building an international team.
“While our primary competitors are focused on concocting their next stage of funding, Clinical Ink is hiring the best people in the industry to better deliver for our customers,” said Clinical Ink CEO Ed Seguine. “As a profitable, mature company and undisputed eSource leader, we are building out our global customer support infrastructure to ensure our explosive growth does not outstrip our ability to provide unparalleled customer service; Janette brings tremendous expertise to our executive team and is the right person to build out our international operations.”
Mark Sitcoske (founder and CEO of High Purity New England) has been elected to the board of directors of the Bio-Process Systems Alliance (BPSA). The alliance is an industry association dedicated to encouraging and accelerating adoption of single-use manufacturing technologies.
“I was glad to be considered and chosen for the position, considering the competition for the seat,” Sitcoske commented. “I am honored to be able to work with others in the industry to facilitate the development and manufacturing of safe, sustainable single-use technologies.”
Contract development and manufacturing organization (CDMO) Experic has appointed David Wood as chairman and CEO. With more than 30 years of broad industry experience, Wood’s experience includes stints at Captek Softgel International, Catalent Pharma Solutions, Cardinal Health and Becton Dickinson.
“We are thrilled to have Dave accept this leadership role at Experic,” said Tom Weller, Experic board member and CEO of Harro Höfliger. “He brings the right mix of industry experience and strategic thinking to help take the company to its next phase of growth.”
Life-sciences supplier Aceto has acquired a majority stake in Finar Limited, a provider of excipients, lab chemicals and other gear. The move is intended to complement Aceto’s growth strategy, expanding its manufacturing footprint, R&D capabilities, and expertise.
“We are excited to bring together Finar and Aceto to give customers of both companies more solutions to support their supply chains globally,” said Gilles Cottier, CEO of Aceto. “With the Finar team’s help, we continue to strengthen our manufacturing expertise and expand our product offerings for the pharmaceutical, biopharmaceutical, and vaccine end markets.”
Global pharma supplier has announced two senior-executive appointments, both of whom will work out of the company’s R&D facility in Germany. Daniel Illmer has been named design head for encapsulation; Afsaneh Nakhavoli has joined the firm as design head for tableting. Both join the company’s R&D facility in Germany.
“I am delighted to welcome Daniel and Afsaneh to the ACG team,” said Werner Bongers, CEO of scitech for ACG. “Design heads are pivotal to our business and their wealth of industry experience will help drive innovation and underpin the continued global growth of ACG.”
The Foundation for Angelman Syndrome Therapeutics (FAST) has announced its campaign with NASCAR driver Cameron Lawrence to raise awareness for the rare disease. With the support of benefactors Ryan and Annie Jacob, Lawrence has selected FAST the team’s prefered non-profit for his upcoming NASCAR Camping World Truck Series debut at Circuit of the Americas.
“NASCAR Camping World Truck Series is an incredible platform to raise awareness; we hope to capitalize on that during the upcoming event at Circuit of the Americas,” said John Schlueter, chairperson for the FAST board of directors. “Our campaign with Cameron Lawrence is a unique opportunity to reach a brand-new audience, which we hope will be inspired to join us in our fight to find a cure for Angelman syndrome.”
Institutional review board Sterling IRB is commemorating its 30th anniversary this year. The veteran-owned company offers central and local IRB services, reportedly with the goal of avoiding some of the bottlenecks commonly associated with larger review boards.
“We are excited to mark this significant anniversary in the company’s history by investing in a brand which embodies the continued excellence we look forward to providing research participants and our clients well into the future,” said Ted Green, president and CEO of Sterling IRB. “As our longtime clients know, the brand communicates our commitment to safeguarding research and when organizations need a dedicated IRB, Sterling IRB is dedicated to providing expert guidance.”
